Kodiak Sciences Inc
KOD
Jodie situation report
Kodiak Sciences Inc's move is being confirmed by its market group.
No new filing conclusion is available. 8 of 15 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.
- At least 10 of 15 durable members become active together.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as ABBV begins moving with the group.
Invalidation: The live read weakens if participation falls to 5 of 15 members or fewer.
Who this business touches
The relationships behind KOD
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
NVSNovartis AGcompetitorMay 7, 2026 ▾
“Several of our competitors have commercially approved products for the treatment of retinal diseases that we are pursuing or may pursue in the future, including Roche, Regeneron and Novartis for the treatment of wet AMD, DME, DR and RVO.”
REGNRegeneron Pharmaceuticals, Inc.competitorMay 7, 2026 ▾
“6 Regeneron’s Eylea HD is a major competitive product, with FDA approvals across wet AMD, DME, DR and RVO.”
Depended on by
FDMT4D Molecular Therapeutics, Inc.competitorMar 18, 2026 ▾
“We also face competition from late-stage sustained release VEGF receptor tyrosine kinase 11 inhibitor programs at EyePoint Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
KOD is currently a Participant in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.